(Q41248630)

28 September 2017

Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer's Disease (English)

1 reference

28 September 2017

0 references

3

Heii Arai

1 reference

28 September 2017

Michael Hull

1

1 reference

28 September 2017

Carl Sadowsky

2

1 reference

28 September 2017

Ghislaine Le Prince Leterme

4

1 reference

28 September 2017

Ann Holstein

5

1 reference

28 September 2017

Kevin Booth

6

1 reference

28 September 2017

Yahong Peng

7

1 reference

28 September 2017

Tamotsu Yoshiyama

8

1 reference

28 September 2017

Hideo Suzuki

9

1 reference

28 September 2017

Nzeera Ketter

10

1 reference

28 September 2017

Enchi Liu

11

1 reference

28 September 2017

J Michael Ryan

12

1 reference

28 September 2017

16 January 2017

1 reference

Current Alzheimer Research

28 September 2017

1 reference

28 September 2017

14

1 reference

28 September 2017

7

1 reference

28 September 2017

696-708

1 reference

Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's Disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

Control of hypertension with medication: a comparative analysis of national surveys in 20 countries

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

Epidemiology of hypertension in Japan: where are we now?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: results from two phase 2 studies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

A phase 3 trial of semagacestat for treatment of Alzheimer's disease

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543567

10.2174/1567205014666170117101537

19 August 2018

Identifiers

DOI

1 reference

28 September 2017

1 reference

28 September 2017

1 reference